Tommy Kenny: Thank you, Hugh.
Operator: Thank you. And the next question is coming from Lindsey Murphy. Lindsey is a private investor. Lindsey, your line is live.
Lindsey Murphy: Hi. Thank you for taking my call. I just had a quick question and was wondering if there was any update on the VevaDerm?
Horst Zerbe: Which one? I missed that acoustically.
Lindsey Murphy: It was the VevaDerm. If there was any update with the VevaDerm.
Frank Pietrantonio: I think she mean VevaDerm, which is our trademark for transdermal.
Lindsey Murphy: Okay. Yes, I briefly commented on that before. We are in active discussions with a European company about two transdermal programs. So we have determined that the transdermal space, and that’s where VevaDerm, the name comes from is an attractive technology and an attractive market for us. So we’re actively pursuing that. And like I said two €“ we’re discussing two opportunities. However, that’s early stage. So it’ll be a while until we can do €“ we’ll be able to present any more tangible or advanced project. But principally speaking, there is definite activity in that space.
Lindsey Murphy: Okay. Thank you. I really appreciate it. I apologize I missed that earlier.
Horst Zerbe: No problem.
Operator: Thank you. And we have a follow-up coming from Trevor Lee . Trevor, your line is live.
Unidentified Analyst: Hey, I just had one more thing I was just thinking of while listening. I know in the past, Horst you said like you don’t want to €“ you’re not about releasing fluff news or anything that’s not concrete. Have you considered, just doing more to bring awareness to the company? Like, if we need to raise capital in the future, I think bringing in investors or just bringing in awareness to the company couldn’t hurt. Like you having more of a social media presence or on Twitter with just leading people to the company via information about Alzheimer’s or some of the €“ some of the causes that we’re looking to help. Is that anything that you might be interested in?
Horst Zerbe: We definitely are. That is actually a subject that we’re discussing very often and regularly. I mean, as far as outreach to investors is concerned that is in Andre’s domain. He’s doing that. I think going forward and that was one of the many reasons as to why we brought David in. He will be supported by David, who has pretty significant capital markets expertise beside his BD background. We also have a communications group that regularly discusses what we can do in terms of bringing our message to investors. So we’re trying to be more active in that space. It is recognized as an area that we need to step up our efforts. Tommy, with you being a member of that group, if you want to add anything, be free.
Tommy Kenny: Yes, we know that we need to improve on the social media front. As for the hard news, the press releases, I mean, what you said is consistent. We want to only release things that are material and we don’t want to release press release about nothing. So we will work as hard as we can to improve our social media presence, but the press release will remain hard news as the investor would expect it and not those press release that means nothing.
Unidentified Analyst: That sounds good. Yes, I think €“ I think the company could definitely benefit from just more of a presence just to bring awareness. Power of the retail investors has definitely grown as well in the past couple years. I get to piggyback off that, maybe more presence at conferences and stuff like that. I was curious if there was any sort of, anything happened at the Roth conference on the West Coast like Andre
Horst Zerbe: That’s Andre’s area.
Andre Godin: Yes. I mean that was actually a very good conference. I met a lot of investors as well as Roth analysts, so we’re expecting to get some good feedback from that. There is obviously since we’re on the bulletin board in the U.S. sometimes it’s €“ it might be a little bit difficult to attract a lot of healthcare institution. But I think that being on the big board in Toronto that has improved our ability to attract healthcare institution from the U.S. But yes, there was good meeting and we’re expecting more coverage too there. We were present at €“ also at JP Morgan, not at the big conference, but €“ and there was a lot of interest from different banks and different analysts. So we’re pushing towards that direction to get more coverage. We have one coverage right now from Canada, but I think that we’re expecting an opening to get a few more from the U.S.
Unidentified Analyst: Yes. I think that would go a long way like more analyst coverage and stuff, but…
Andre Godin: Yes definitely.
Unidentified Analyst: Yes. That’s all I had for today guys.
Andre Godin: Thank you.
Horst Zerbe: Thank you.
Operator: Thank you. And we have a question from James Larcom from Ontario Limited . James, your line is live.
